FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Issues > Population-Wide BRCA Testing


FORCE is supporting legislation (H.R. 4078) to reauthorize and increase funding for the Breast Cancer Education and Awareness Requires Learning Young Act (EARLY) Act.

We played a lead role in drafting coalition comments on the FDA's proposed mammography guideline updates.

FORCE recommendations regarding genomics were accepted and will be integrated into the Healthy People 2030 objectives.

Today, the FDA announced a new pilot program called Project Facilitate to assist oncologists in requesting access to unapproved therapies for cancer patients. 

We signed onto coalition letters to the House and Senate regarding FY20 funding for the Defense Health Research programs. 

Population-Wide BRCA Testing

Genetic Testing & Counseling


In 2014, Dr. Mary-Claire King, whose research led to the discovery of the BRCA1 gene associated with hereditary breast cancer and ovarian cancer, proposed that genetic testing for the BRCA1 and BRCA2 gene mutations become routine for all U.S. women over age 30. Among other things, King cited an Israeli study which revealed that Ashkenazi Jewish women with no family history of cancer—but who tested positive for a BRCA genetic mutation—have high rates of breast and ovarian cancer. 

Demonstration studies in the Ashkenazi Jewish population have shown that screening for the three BRCA founder mutations may be cost-effective and identifies carriers who would not have been suspected on the basis of their family cancer history. However, applying this to the broader, more diverse U.S. population may not yield the same results.

FORCE continues to consult with its scientific advisory board and other experts to evaluate these proposed changes and their implications on health care practice.

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered